<DOC>
	<DOC>NCT01856309</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of CNTO 136 (sirukumab) in participants with rheumatoid arthritis (RA) who are unresponsive to treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents.</brief_summary>
	<brief_title>Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003</brief_title>
	<detailed_description>This is a multicenter, long-term study of sirukumab (CNTO 136) that will be conducted in two groups of participants at the same time (parallel-group study). The maximum duration of participation in this study is 208 weeks, followed by approximately 16 weeks of safety and efficacy follow-up after the administration of the final study agent injection of sirukumab. Participant safety will be monitored throughout the study.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Completed participation in Studies CNTO136ARA3002 or CNTO136ARA3003 Signed an informed consent form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study Signed an informed consent form (ICF) for pharmacogenetics research (how a person's genes may affect a drug's effects) in order to participate in the optional pharmacogenetics component of this study. Refusal to give consent for this component does not exclude a participant from participation in this clinical study Withdraws consent and/or discontinues participation in study CNTO136ARA3002 or CNTO136ARA3003 Is pregnant Has active diverticulitis Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (eg, compromise the wellbeing) of the participant or that could prevent, limit, or confound the protocolspecified assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Sirukumab</keyword>
	<keyword>CNTO 136</keyword>
	<keyword>CNTO136ARA3002</keyword>
	<keyword>SIRROUND-D</keyword>
	<keyword>CNTO136ARA3003</keyword>
	<keyword>SIRROUND-T</keyword>
	<keyword>SIRROUND-LTE</keyword>
</DOC>